Business
Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be made available through direct-to-patient platforms in 2026Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to low
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":287,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jVHT.jc1r.9_PBg7JQVa4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTgwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/838a2f0cbe482ce95bb28a161721a308","width":287,"height":55}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional Novartis medicines will be made available through direct-to-patient platforms in 2026","length":96,"tagName":"p"}]},{"val":[{"type":"text","content":"Company remains committed to investing in markets that value innovation and implement policies that support broad and fast access to medicines","length":142,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":332,"olType":false},{"type":"text","content":"Basel, December 19, 2025 – Novartis, a leading global innovative medicines company, today announced it has reached an agreement with the US government that aims to lower the price of innovative medicines in the US and support continued US investment in manufacturing, and research and development.","length":297,"tagName":"p"},{"type":"text","content":"Novartis has voluntarily agreed to take actions aimed at meeting the US Administration’s drug pricing priorities, including:","length":124,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Launching future medicines with comparable prices across high-income countries","length":78,"tagName":"p"}]},{"val":[{"type":"text","content":"Building direct-to-patient platforms for Mayzent® (siponimod), Rydapt® (midostaurin) and Tabrecta® (capmatinib). These new platforms will be accessible through TrumpRx","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"Applying to participate in the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model aimed at further improving access to medicines in the US Medicaid program","length":171,"tagName":"p"}]},{"val":[{"type":"text","content":"Supporting efforts to address the global imbalanc...